Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1168
Abstract: Dysphagia is highly prevalent in patients with amyotrophic lateral sclerosis (ALS). Riluzole is a US Food and Drug Administration‐approved treatment for ALS. Riluzole oral film (ROF; Exservan™) contains riluzole in a polymer‐based film matrix. The… read more here.
Keywords: safety; bioavailability; oral film; rof ... See more keywords